Teva Could Face Damages Of $1.2 Billion For At-Risk Launch Of Generic Protonix

A jury finds that Pfizer's patent on the proton pump inhibitor is valid; analyst Timothy Anderson estimates that without a settlement Teva's damages could top $1 billion but thinks the actual impact will be smaller.